聚乳酸、聚乳酸乙醇酸共聚物微球的制备及影响其质量因素的研究进展

164
Foreign Medical Sciences Section on Pharmacy 2001 Jun ; 28 (3)
[20 ] Theo JC , Marc CM , Bijsterbosch MK, et al. Drug targeting
by neo2lipoproteins [J ]. J Controlled Release , 1996 , 41
(1) :85 - 90.
[21 ] Higashi S , Tabata N , Kondo K, et al. Size of lipid micro2
droplets effects results of hepatic arterial chemotherapy with
an anticancer agent in water2in2oil2in2water emulsion to hep2
atocellular carcinoma [J ]. J Pharmacol Exp Ther , 1999 ,
289 (2) :816 - 819.
1 ,
1
2 (1.
, 830054 ; 2.
, 110015)
:
,
,
: ;
;
: R943
: A : 100120971 (2001) 0320164204
,
,
(solvent
evaporation2extraction)
(PACA) ( DCM)
(ACN) , DCM ,W/
,O/ W
(TNF ) , TNF
, Iwata
(LA) ( GA) LA D2L2
[8 ] ( anhydrous multiple
DL2,
D2 emulsion evaporation or non aqueous solvent evaporation)
(PLA) L2PLA DL2PLA ;GA
TNF ,
O/ O D2
( D2PLGA) L2PLGA
,
DL2PLGA PLA PLGA
:
2 %
140 ,
,
1 g
3. 25 g 1
(4 % span 80) ,
S/ O ,
1. 1
1 g
7 g PLGA2ACN (28. 6 %)
, PLA PLGA
, S/ O/ O , 70 g 0. 5 %
span 80 ,S/ O/ O/ O ,400500 r
, min - 1
24 h , ACN 50
m , n2 2 % Tween280 , 3 ,
[1 ,2
] , 24 h
80 %
,
ACN ,
(modified solvent evaporation or
[35
multiple emulsion solvent evaporation)
] 1. 2
,
,
,
:2000207207
[6 ,7 ]
,Bodmeier [9 ]
,

2001 6
28 3
165
CO 2 ,
,Ertl [14 ] H PLGA
CO 2
(camptothecin)
PLA ,PLGA
( EC) , PLGA
,
H
,
,
PLGA
2
, (60 ) 2. 2
CO 2
En2
2 PLA PL GA
,
2. 1
2. 1. 1 ,PLA ,
PLA
,,
,
, 2. 3
Shenderova [10 ]
2. 3. 1
,
,
2. 1. 2 PLA
, PLA ,
(
[10 ]
PLGA
,
2
) O Donnell [15 ] O/ W ,O/ O ,W/ O/ W ,
,
PLGA W/ O/ O/ O
PLA
PLGA( 10 00064 000)
,
PLGA ,
PLA O/ W ,
PLGA
, PLA PLGA
,
PLA
(43. 8 %) , 23 % ;W/ O/ W
[11
,
] Delgado [12 ] 69 % , 99. 5 % , W/ O/ W
DL2PLA
(methadone)
,W/ O/ O/ O 3 ,
100 % ,
,
330063 000 PLA
, ,
,
,W/ O/ W
2. 1. 3 PLGA LA/ GA Heller
,
12. 87 ,74. 26 25. 74
PLGA
,
,
( 63125m) ,
O/ O
, 58 %
180200 d 48 h ,6 d
, GA ,
,
LA/ GA
,
,
2. 1. 4 Schrier [13 ]
,
W/ O/ W
22 (rhBMP2
6 d ,14 d ,
2) PLGA LA/ GA W/ O/ O/ O ,48 h 12 % ,
, ,
: > > LA/ GA ,
,
doh [1 ]
FudR
,
, 20 % ;O/ O
LA GA
100 0 ,92. 8 7. 2 ,87. 13 ,
O/ W
,O/ O ,
,
W/ O/
O/ O W/ O
,40 3

166
Foreign Medical Sciences Section on Pharmacy 2001 Jun ; 28 (3)
,W/ O/ O/ O
,O/ W
, O/ W
,
,
[6
] Li [7 ] [1 ] Endoh H , Kawaguchi T , Seki T , et al. Controlled release
of 52fluoro22 deoxyuridine by the combination of prodrug and
,
/ ( ) polymer matrix[J ]. Chem Pharm Bull (Tokyo) , 1991 , 39
(2) :458 - 464.
,
acterization of poly(lactic2co2glycolic acid) microspheres for
,
targeted delivery of a novel anticancer agent , taxol [J ].
, ,
,
Chem Pharm Bull (Tokyo) , 1996 , 44(10) :1935 - 1940.
2. 3. 2
,
,
lease of a water2soluble GP b/ a antagonist from copoly
, ( DL2lactic/ glycolic) acid microspheres[J ]. Int J Pharm ,
,
1997 , 146(2) :147 - 157.
[15
]
[4 ] Celebi N , Erden N , T rkyilmaz A. The preparation and
evaluation of salbutamol sulphate containing PLGA
2. 4
micro2
, ,
[15
] Pharm , 1996 , 136(1/ 2) :89 - 100.
,
[5 ] Herrmann J , Bodmeier R. The effect of particle microstruc2
,
ture on the somatostatin release from poly(lactide) micro2
[2
] ,PLGA DCM 30 %
spheres prepared by a W/ O/ W solvent evaporation method
( IPM) 3
70 %
,IPM 50 %[6 ] , , , .
,IPM
[J ]. W/ O/ W
, 1997 , 32(10) :595 - 597.
[11
(somatostatin)
] ,
() [7 ] Li WI , Anderson KW , Mehta RC , et al. Prediction of sol2
( vent removal profile and effect on properties for
pH 2 . 2 ,3 . 0 , 4 . 0 , 5 . 0)
peptide2
loaded PLGA microspheres prepared by solvent2extraction
(NaCl ,CaCl 2 )
(3) :199 - 214.
,
,
[8 ]
,
L2
,
colic acid) microspheres containing tumor necrosis factor2al2
pha (TNF2 ) [J ]. Int J Pharm , 1998 , 160(2) :145 - 156.
PVA NaCl [9 ] Bodmeier R , Wang H , Dixon DJ , et al. Polymeric micro2
Reich [16 ]
,
spheres prepared by spraying into compressed carbon dioxide
PLGA ,
DCM [10 ] Shenderova A , Burke TG, Schwendeman SP. Stabilization
,
of 102hydroxycamptothecin in poly(lactide2co2glycolide) mi2
3
(10) :1406 - 1414.
PLA PLGA
[2 ] Wang YM , Sato H , Adachi I , et al. Preparation and char2
[3 ] Takada S , Kurokawa T , Miyazaki K, et al. Sustained re2
spheres with factorial design2based studies [ J ]. Int J
[J ]. J Controlled Release , 1995 , 36(1/ 2) :63 - 71.
evaporation method [J ]. J Controlled Release , 1995 , 37
Iwata M , Tanaka T , Nakamura Y, et al. Selection of sol2
vent system for the preparation of Poly( D , L2lactic2co2gly2
[J ]. Pharm Res , 1995 ,12(8) :1211 - 1217.
crosphere delivery vehicles [ J ]. Pharm Res , 1997 , 14
[11 ] Corre PL , Guevello PL , Gajan V , et al. Preparation and
,
characterization of bupivacaine2loaded polylactide and poly2
,
lactide2co2glycolide microspheres[J ]. Int J Pharm , 1994 ,
107 (1) :41 - 49.
,
[12 ] Delgado A , Evora C , Llabr s M. Effect of storage on the

2001 6
28 3
167
stability of DL2PLA microspheres containing methadone[J ].
Int J Pharm , 1998 , 166(2) :223 - 225.
[13 ] Schrier JA , DeLuca PP. Recombinant human bone morpho2
genetic protein22 binding and incorporation in PLGA micro2
sphere delivery systems[J ]. Pharm Dev Technol , 1999 , 4
(4) :611 - 612.
[14 ] Ertl B , Platzer P , Wirth M , et al. Poly ( D , L2lactic2co2
glycolic acid) microspheres for sustained delivery and stabi2
lization of camptothecin[J ]. J Controlled Release , 1999 , 61
(3) :305 - 317.
[15 ] O Donnell PB , McGinity JW. Influence of processing of the
stability and release properties of biodegradable microspheres
containing thioridazine hydrochloride[J ]. Eur J Pharm Bio2
pharm , 1998 , 45(1) :83 - 94.
[16 ] Reich G. Ultrasound2induced degradation of PLA and PLGA
during microsphere processing : influence of formulation vari2
ables[J ]. Eur J Pharm Biopharm , 1998 , 45 (2) : 165 -
171.
, ,
(
, 200433)
:
,
: ; ; ; ;
: R944. 2
: A : 100120971 (2001) 0320167204
,
,DPI
,
,
,DPI
[1 ] ,
,
[2
] DPI
(
) ,
, ,
1
DPI
,
,,
[3
] Bell
(chlorofluorocarban , CFC)
[4 ] 1971
DPI ,
, CFC (ozone
friendly replacement propellants)
,
,
( )
,
, ,
,
,
(
25 %) ,Easyhaler R
,Diskhaler R
,Rothaler R
,
(dry powder inhalers , DPI) ,
[3 ,5
]
,
,
2
, 10
DPI
:2000207204
DPI
,